摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(Z)-2-[(6-amino-5,7,8,13-tetraazadibenzo[a,e]azulen-7-yl)methyl]-3-phenylprop-2-enenitrile | 1141932-87-7

中文名称
——
中文别名
——
英文名称
(Z)-2-[(6-amino-5,7,8,13-tetraazadibenzo[a,e]azulen-7-yl)methyl]-3-phenylprop-2-enenitrile
英文别名
(Z)-2-[(9-amino-8,10,12,18-tetrazatetracyclo[9.7.0.02,7.012,17]octadeca-1(11),2,4,6,8,13,15,17-octaen-10-yl)methyl]-3-phenylprop-2-enenitrile
(Z)-2-[(6-amino-5,7,8,13-tetraazadibenzo[a,e]azulen-7-yl)methyl]-3-phenylprop-2-enenitrile化学式
CAS
1141932-87-7
化学式
C24H18N6
mdl
——
分子量
390.447
InChiKey
PIOSBUCIUWCSPY-NBVRZTHBSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3.9
  • 重原子数:
    30
  • 可旋转键数:
    3
  • 环数:
    5.0
  • sp3杂化的碳原子比例:
    0.04
  • 拓扑面积:
    82.7
  • 氢给体数:
    1
  • 氢受体数:
    3

反应信息

  • 作为产物:
    描述:
    溴化氰 、 在 potassium carbonate 作用下, 以 四氢呋喃 为溶剂, 反应 9.0h, 以0.120 g的产率得到(Z)-2-[(6-amino-5,7,8,13-tetraazadibenzo[a,e]azulen-7-yl)methyl]-3-phenylprop-2-enenitrile
    参考文献:
    名称:
    利用Baylis-Hillman加合物首次合成烯丙基异腈,并将其应用于取代的咪唑并[1,2-a]吡啶和四氮杂二苯并氮杂蒽酮的合成中
    摘要:
    由Baylis-Hillman加合物生成的伯烯丙胺立体选择性合成取代的烯丙基异腈的首次报道,以及它们在氯化铵存在下在基于鲁棒的基于异腈的多组分反应中的应用,从而获得了取代的咪唑并[1,2- a ]吡啶说明。 异腈-Baylis-Hillman-烯丙胺-多组分反应-咪唑并[1,2- a ]吡啶 CDRI通讯第7599号。
    DOI:
    10.1055/s-0028-1083306
点击查看最新优质反应信息

文献信息

  • The First Synthesis of Allyl Isonitriles from Baylis-Hillman Adducts, and Their Application in the Synthesis of Substituted Imidazo[1,2-<i>a</i>]pyridines and Tetraazadibenzoazulenes
    作者:Sanjay Batra、Maloy Nayak、Sanjeev Kanojiya
    DOI:10.1055/s-0028-1083306
    日期:——
    synthesis of substituted allyl isonitriles from primary allylamines generated from Baylis­-Hillman adducts, and their utilization in a robust isonitrile-based multicomponent reaction in the presence of ammonium chloride to afford substituted imidazo[1,2-a]pyridines, is described. isonitriles - Baylis-Hillman - allylamines - multicomponent reactions - imidazo[1,2-a]pyridines CDRI Communication No. 7599.
    由Baylis-Hillman加合物生成的伯烯丙胺立体选择性合成取代的烯丙基异腈的首次报道,以及它们在氯化铵存在下在基于鲁棒的基于异腈的多组分反应中的应用,从而获得了取代的咪唑并[1,2- a ]吡啶说明。 异腈-Baylis-Hillman-烯丙胺-多组分反应-咪唑并[1,2- a ]吡啶 CDRI通讯第7599号。
查看更多

同类化合物

脱氧助间型霉素 化合物RK-33 8-叔-丁基1-乙基6,7-二氢-5H-咪唑并[1,5-A][1,4]二氮杂卓-1,8(9H)-二甲酸基酯 8-(叔丁氧羰基)-6,7,8,9-四氢-5H-咪唑并[1,5-A][1,4]二氮杂-1-羧酸 6-羟基-4,5,6,7-四氢咪唑并[4,5-e][1,4]二氮杂卓-8(1H)-酮 5-(8-羟基-7,8-二氢-4H-咪唑并[5,4-d][1,3]二氮杂卓-3-基)-3-(羟基甲基)环戊-3-烯-1,2-二醇 4,7-二氢咪唑并[4,5-d][1,3]二氮杂卓-8(1H)-酮 3-[(2-羟基乙氧基)甲基]-3,4,7,8-四氢咪唑并[4,5-d][1,3]二氮杂卓-8-醇 1H-咪唑并[1,5-d〕〔1,4]二氮杂(9CI) 1,4,6,7-四氢咪唑并[4,5-e][1,4]二氮杂卓-5,8-二酮 (9ci)-1H-咪唑并[1,2-a][1,4]二氮杂卓 5-methylthio-11H-imidazo[1,2-c][1,3]benzodiazepine 2-methoxy-1,4,7-trimethyl-4,5,7,8-tetrahydro-6H-imidazo<4,5-e><1,4>diazepine-5,8-dione 1-benzyl-5,7-diphenyl-4,5,7,8-tetrahydroimidazo<4,5-e><1,3>diazepin-6-one 6-amino-4,5-dihydro-8H-imidazo[4,5-e][1,3]diazepine-4,8-dione [3-(2-Deoxy-β-D-erythro-pentofuranosyl)-3,6,7,8 tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol]-5'-phosphoric Acid-(3-dodecylmercapto-2-decyloxy)-propyl Ester (4S)-4-benzyl-2-(2,5-dihydroxyphenyl)-3,4-dihydro-5H-pyrido[1',2':1,2]imidazo-[4,5-d][1,3]diazepin-5-one (4S)-4-benzyl-2-(2,5-dimethoxyphenyl)-3,4-dihydro-5H-pyrido[10,20:1,2]imidazo [4,5-d][1,3]diazepin-5-one (4S)-4-methyl-2-(1-naphthyl)-3,4-dihydro-5H-pyrido[1',2':1,2]imidazo-[4,5-d][1,3]diazepin-5-one 6-amino-1-(2'-deoxy-β-D-erythropentofuranosyl)-4,5-dihydro-8H-imidazo[4,5-e][1,3]diazepine-4,8-dione 6-amino-1-(2'-deoxy-α-D-erythropentofuranosyl)-4,5-dihydro-8H-imidazo[4,5-e][1,3]diazepine-4,8-dione (4S)-4-methyl-2-(4-acetamidophenyl)-3,4-dihydro-5H-pyrido[1',2':1,2]imidazo-[4,5-d][1,3]diazepin-5-one 5-(4-methyl-1-piperazinyl)-11H-imidazo[1,2-c][1,3]benzodiazepine monomaleate (8R)-3-[(4R,5S)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7,8-dihydro-4H-imidazo[4,5-d][1,3]diazepin-8-ol (R)-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol 6-(decylamino)-1-[(2S,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7H-imidazo[4,5-e][1,3]diazepine-4,8-dione (13S)-11-(4-methoxyphenyl)-13-methyl-2,8,10,12-tetrazatricyclo[7.5.0.02,7]tetradeca-1(9),3,5,7,11-pentaen-14-one (8R)-3-[(2S,4S,5S)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7,8-dihydro-4H-imidazo[4,5-d][1,3]diazepin-8-ol 8-Ketodeoxycoformycin 2'-chloropentostatin CO-Vidarabine (8R)-3-[(1S,2R,4R)-2-(benzoyloxymethyl)-1-benzoyloxycyclopent-4-yl]-8-[(tert-butyldimethylsilyl)oxy]-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepine (8R)-3-Benzyl-6-(tert-butoxycarbonyl)-8-<(tert-butyldimethylsilyl)oxy>-3,6,7,8-tetrahydroimidazo<4,5-d><1,3>diazepine (8R)-3-(2'-Cyanoethyl)-8-<(tert-butyldimethylsilyl)oxy>-3,6,7,8-tetrahydroimidazo<4,5-d><1,3>diazepine 4-propyl-4,5,7,8-tetrahydro-6H-imidazo<4,5-e><1,4>diazepine-5,8-dione 1-benzyl-4-propyl-4,5,7,8-tetrahydro-6H-imidazo<4,5-e><1,4>diazepine-5,8-dione 4-isobutyl-7-methyl-4,5,7,8-tetrahydro-6H-imidazo<4,5-e><1,4>diazepine-5,8-dione 1-benzyl-4,7-diethyl-4,5,7,8-tetrahydro-6H-imidazo<4,5-e><1,4>diazepine-5,8-dione 1-benzyl-4-isobutyl-7-methyl-4,5,7,8-tetrahydro-6H-imidazo<4,5-e><1,4>diazepine-5,8-dione 4,6-diamino-6-(ethylimino)-1,6-dihydroimidazo[4,5-e][1,3]diazepine 4,5-dihydro-8H-6-(N-hexadecyl)amino-1-(2'-deoxy-α-D-erythropentofuranosyl)imidazo[4,5-e]diazepine-4,8-dione 4,5-dihydro-8H-6-(N-tetradecyl)amino-1-(2'-deoxy-α-D-erythropentofuranosyl)imidazo[4,5-e]diazepine-4,8-dione 4,5-dihydro-8H-6-(N-octadecyl)amino-1-(2-deoxy-α-D-erythropentofuranosyl)imidazo[4,5-e]diazepine-4,8-dione 4,6-diamino-6-(octadecylimino)-1,6-dihydroimidazo[4,5-e][1,3]diazepine 8-Imino-2,4-dimethyl-7-phenyl-7,8-dihydro-4H-1,2a,4,5,7-pentaaza-cyclopenta[cd]azulene-3,6-dione 1,4-dimethyl-4,5,7,8-tetrahydro-6H-imidazo<4,5-e><1,4>diazepine-5,8-dione 11H-imidazo[1,2-c][1,3]benzodiazepine-5(6H)-thione (8R)-3-[(4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7,8-dihydro-4H-imidazo[4,5-d][1,3]diazepin-8-ol 2-(4-Chloro-benzylcarbamoyl)-6-(8-hydroxy-7,8-dihydro-6H-imidazo[4,5-d][1,3]diazepin-3-yl)-hexanoic acid benzyl ester (13S)-13-(1H-indol-3-ylmethyl)-2,8,10,12-tetrazatricyclo[7.5.0.02,7]tetradeca-1(9),3,5,7-tetraene-11,14-dione